Adrenergic beta-2 Receptor Agonists
"Adrenergic beta-2 Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.
| Descriptor ID |
D058666
|
| MeSH Number(s) |
D27.505.519.625.050.100.200.200 D27.505.696.577.050.100.200.200
|
| Concept/Terms |
Adrenergic beta-2 Receptor Agonists- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta 2 Receptor Agonists
- Adrenergic beta2-Agonists
- Adrenergic beta2 Agonists
- beta2-Agonists, Adrenergic
- Adrenergic beta-2 Agonists
- Adrenergic beta 2 Agonists
- Agonists, Adrenergic beta-2
- beta-2 Agonists, Adrenergic
- Adrenergic beta-2 Receptor Agonist
- Adrenergic beta 2 Receptor Agonist
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic beta-2 Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic beta-2 Receptor Agonists".
This graph shows the total number of publications written about "Adrenergic beta-2 Receptor Agonists" by people in this website by year, and whether "Adrenergic beta-2 Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic beta-2 Receptor Agonists" by people in Profiles.
-
Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:1377-1388.
-
Mitochondrial biogenesis induced by the ?2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury. Kidney Int. 2019 09; 96(3):656-673.
-
Beta2-adrenergic receptor in kidney biology: A current prospective. Nephrology (Carlton). 2019 May; 24(5):497-503.
-
Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opin Pharmacother. 2019 Jun; 20(9):1075-1085.
-
Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved ?2-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury. J Neurotrauma. 2019 03 19; 36(6):962-972.
-
A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. Expert Opin Pharmacother. 2017 Dec; 18(17):1833-1843.
-
Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy. Int J Chron Obstruct Pulmon Dis. 2017; 12:135-140.
-
Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment. J Manag Care Spec Pharm. 2016 Mar; 22(3):293-304.
-
Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. Int J Chron Obstruct Pulmon Dis. 2015; 10:2055-66.
-
Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015 Feb; 16(3):427-34.